Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The Chemokine, CCL20, and Its Receptor, CCR6, in the Pathogenesis and Treatment of Psoriasis and Psoriatic Arthritis

The Chemokine, CCL20, and Its Receptor, CCR6, in the Pathogenesis and Treatment of Psoriasis and... BackgroundChemokines represent a superfamily of immune-modulatory small protein molecules that regulate leukocyte migration to inflammatory sites through their chemoattractant and cell signaling properties. This review focuses on the immunological functions of the CCR6 chemokine receptor and is chemokine ligand, CCL20, that contribute to it role in inflammation in human psoriasis.MethodsPeer-reviewed relevant articles are searched and selected from 2000 to 2022 using the search engines including PubMed and Google Scholar.ResultsAfter selectively reviewing and evaluating over seventy articles, a comprehensive overview on the immunology of CCL20-CCR6 axis in psoriasis and psoriatic arthritis, the X-ray crystal structures of CCL20 monomers, and the potential of developing clinical therapies targeting this axis is summarized.ConclusionsOver the past decade, preclinical studies carried out in animal models of psoriasis involving agents targeting CCL20-CCR6 axis have yielded promising results. Other studies that this axis may play a role in a number of other autoimmune diseases, including rheumatoid arthritis, suggesting a rationale for further investigation into this key signaling/migratory pathway. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Psoriasis and Psoriatic Arthritis SAGE

The Chemokine, CCL20, and Its Receptor, CCR6, in the Pathogenesis and Treatment of Psoriasis and Psoriatic Arthritis

Download PDF
11 pages

Loading next page...
 
/lp/sage/the-chemokine-ccl20-and-its-receptor-ccr6-in-the-pathogenesis-and-vP7FYvWYZI
Publisher
SAGE
Copyright
© The Author(s) 2023
ISSN
2475-5303
eISSN
2475-5311
DOI
10.1177/24755303231159106
Publisher site
See Article on Publisher Site

Abstract

BackgroundChemokines represent a superfamily of immune-modulatory small protein molecules that regulate leukocyte migration to inflammatory sites through their chemoattractant and cell signaling properties. This review focuses on the immunological functions of the CCR6 chemokine receptor and is chemokine ligand, CCL20, that contribute to it role in inflammation in human psoriasis.MethodsPeer-reviewed relevant articles are searched and selected from 2000 to 2022 using the search engines including PubMed and Google Scholar.ResultsAfter selectively reviewing and evaluating over seventy articles, a comprehensive overview on the immunology of CCL20-CCR6 axis in psoriasis and psoriatic arthritis, the X-ray crystal structures of CCL20 monomers, and the potential of developing clinical therapies targeting this axis is summarized.ConclusionsOver the past decade, preclinical studies carried out in animal models of psoriasis involving agents targeting CCL20-CCR6 axis have yielded promising results. Other studies that this axis may play a role in a number of other autoimmune diseases, including rheumatoid arthritis, suggesting a rationale for further investigation into this key signaling/migratory pathway.

Journal

Journal of Psoriasis and Psoriatic Arthritis – SAGE

Published: Jul 1, 2023

Keywords: migration; chemokines; psoriasis; autoimmune disease; cell signaling

References

  • National, regional, and worldwide epidemiology of psoriasis: Systematic analysis and modelling study
    Parisi, R; Iskandar, IYK; Kontopantelis, E
  • Psoriasis
    Boehncke, WH; Schon, MP
  • Psoriasis: Classical and emerging comorbidities
    Oliveira Mde, F; Rocha Bde, O; Duarte, GV
  • The epidemiology of psoriatic arthritis
    Ogdie, A; Weiss, P
  • Secukinumab in plaque psoriasis–results of two phase 3 trials
    Langley, RG; Elewski, BE; Lebwohl, M
  • Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis
    Griffiths, CEM; Strober, BE; van de Kerkhof, P
  • A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis
    Bilal, J; Berlinberg, A; Bhattacharjee, S; Trost, J; Riaz, IB; Kurtzman, DJB
  • Efficacy and safety of guselkumab in patients with active psoriatic arthritis: A randomised, double-blind, placebo-controlled, phase 2 study
    Deodhar, A; Gottlieb, AB; Boehncke, WH
  • Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial
    McInnes, IB; Kavanaugh, A; Gottlieb, AB
  • Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): A randomised, double-blind, placebo-controlled, phase 3 trial
    McInnes, IB; Mease, PJ; Kirkham, B
  • The many roles of chemokines and chemokine receptors in inflammation
    Charo, IF; Ransohoff, RM
  • Chemokine receptors in the pathogenesis and therapy of psoriasis
    Mabuchi, T; Chang, TW; Quinter, S; Hwang, ST
  • The CC chemokine CCL20 and its receptor CCR6
    Schutyser, E; Struyf, S; Van Damme, J
  • CC chemokine ligand 20 and its cognate receptor CCR6 in mucosal T cell immunology and inflammatory bowel disease: Odd couple or axis of evil?
    Lee, AYS; Eri, R; Lyons, AB; Grimm, MC; Korner, H
  • Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: Implications for psoriasis pathogenesis
    Harper, EG; Guo, C; Rizzo, H
  • Airway epithelial cells release MIP-3alpha/CCL20 in response to cytokines and ambient particulate matter
    Reibman, J; Hsu, Y; Chen, LC; Bleck, B; Gordon, T
  • CC chemokine ligand 20 partially controls adhesion of naive B cells to activated endothelial cells under shear stress
    Meissner, A; Zilles, O; Varona, R
  • CCR6 regulates the migration of inflammatory and regulatory T cells
    Yamazaki, T; Yang, XO; Chung, Y
  • CCL20 expression by tumor-associated macrophages predicts progression of human primary cutaneous melanoma
    Samaniego, R; Gutierrez-Gonzalez, A; Gutierrez-Seijo, A
  • Neutrophils produce biologically active macrophage inflammatory protein-3alpha (MIP-3alpha)/CCL20 and MIP-3beta/CCL19
    Scapini, P; Laudanna, C; Pinardi, C
  • Cyto/chemokine profile of in vitro scratched keratinocyte model: Implications of significant upregulation of CCL20, CXCL8 and IL36G in Koebner phenomenon
    Furue, K; Ito, T; Tanaka, Y
  • Modulation of pathogen-induced CCL20 secretion from HT-29 human intestinal epithelial cells by commensal bacteria
    Sibartie, S; O’Hara, AM; Ryan, J
  • The relationship between CCR6 and its binding partners: Does the CCR6-CCL20 axis have to be extended?
    Lee, AYS; Phan, TK; Hulett, MD; Korner, H
  • Human T cells that are able to produce IL-17 express the chemokine receptor CCR6
    Singh, SP; Zhang, HH; Foley, JF; Hedrick, MN; Farber, JM
  • CCR6 marks regulatory T cells as a colon-tropic, IL-10-producing phenotype
    Kitamura, K; Farber, JM; Kelsall, BL
  • Functional expression of chemokine receptor CCR6 on human effector memory CD8+ T cells
    Kondo, T; Takata, H; Takiguchi, M
  • Dermal clusters of mature dendritic cells and T cells are associated with the CCL20/CCR6 chemokine system in chronic psoriasis
    Kim, TG; Jee, H; Fuentes-Duculan, J
  • The CCR6-CCL20 axis in humoral immunity and T-B cell immunobiology
    Lee, AYS; Korner, H
  • CCR6 as a possible therapeutic target in psoriasis
    Hedrick, MN; Lonsdorf, AS; Hwang, ST; Farber, JM
  • CCR6 signaling inhibits suppressor function of induced-Treg during gut inflammation
    Kulkarni, N; Meitei, HT; Sonar, SA
  • Reduced CCR6(+)IL-17A(+)Treg cells in blood and CCR6-dependent accumulation of IL-17A(+)Treg cells in lungs of patients with allergic asthma
    Shen, X; Zhang, H; Xie, H
  • CCR6 as a mediator of immunity in the lung and gut
    Ito, T; Carson, WFt.; Cavassani, KA; Connett, JM; Kunkel, SL
  • CCR6-dependent positioning of memory B cells is essential for their ability to mount a recall response to antigen
    Elgueta, R; Marks, E; Nowak, E
  • CCR6 defines memory B cell precursors in mouse and human germinal centers, revealing light-zone location and predominant low antigen affinity
    Suan, D; Krautler, NJ; Maag, JLV
  • New paradigms in chemokine receptor signal transduction: Moving beyond the two-site model
    Kleist, AB; Getschman, AE; Ziarek, JJ
  • A deliberate approach to screening for initial crystallization conditions of biological macromolecules
    Luft, JR; Collins, RJ; Fehrman, NA; Lauricella, AM; Veatch, CK; DeTitta, GT
  • Data processing and analysis with the autoPROC toolbox
    Vonrhein, C; Flensburg, C; Keller, P
  • MolProbity: All-atom structure validation for macromolecular crystallography
    Chen, VB; Arendall, WB; Headd, JJ
  • MolProbity: all-atom contacts and structure validation for proteins and nucleic acids
    Davis, IW; Leaver-Fay, A; Chen, VB
  • The chemokine X-factor: Structure-function analysis of the CXC motif at CXCR4 and ACKR3
    Wedemeyer, MJ; Mahn, SA; Getschman, AE
  • Engineering and screening the N-terminus of chemokines for drug discovery
    Chevigne, A; Fievez, V; Schmit, JC; Deroo, S
  • Mutation-induced functional alterations of CCR6
    Julian, B; Gao, K; Harwood, BN; Beinborn, M; Kopin, AS
  • Protein engineering of the chemokine CCL20 prevents psoriasiform dermatitis in an IL-23-dependent murine model
    Getschman, AE; Imai, Y; Larsen, O
  • Mutational analysis of CCL20 reveals flexibility of N-terminal amino acid composition and length
    Riutta, SJ; Larsen, O; Getschman, AE; Rosenkilde, MM; Hwang, ST; Volkman, BF
  • Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines
    Proudfoot, AEI; Handel, TM; Johnson, Z
  • Structural basis of CXCR4 sulfotyrosine recognition by the chemokine SDF-1/CXCL12
    Veldkamp, CT; Seibert, C; Peterson, FC
  • Monomeric and dimeric CXCL12 inhibit metastasis through distinct CXCR4 interactions and signaling pathways
    Drury, LJ; Ziarek, JJ; Gravel, S
  • NMR solution structure of murine CCL20/MIP-3alpha, a chemokine that specifically chemoattracts immature dendritic cells and lymphocytes through its highly specific interaction with the beta-chemokine receptor CCR6
    Perez-Canadillas, JM; Zaballos, A
  • Human macrophage inflammatory protein 3alpha: Protein and peptide nuclear magnetic resonance solution structures, dimerization, dynamics, and anti-infective properties
    Chan, DI; Hunter, HN; Tack, BF; Vogel, HJ
  • The structure of human macrophage inflammatory protein-3alpha/CCL20. Linking antimicrobial and CC chemokine receptor-6-binding activities with human beta-defensins
    Hoover, DM; Boulegue, C; Yang, D
  • Structure of human MIP-3alpha chemokine
    Malik, ZA; Tack, BF
  • Structural basis for chemokine receptor CCR6 activation by the endogenous protein ligand CCL20
    Wasilko, DJ; Johnson, ZL; Ammirati, M
  • Immunology of psoriasis
    Lowes, MA; Suarez-Farinas, M; Krueger, JG
  • Epidermal CCR6+ γδ T cells are major producers of IL-22 and IL-17 in a murine model of psoriasiform dermatitis
    Mabuchi, T; Takekoshi, T; Hwang, ST
  • Characterization of innate lymphoid cells in human skin and blood demonstrates increase of NKp44+ ILC3 in psoriasis
    Villanova, F; Flutter, B; Tosi, I
  • Increased number and frequency of group 3 innate lymphoid cells in nonlesional psoriatic skin
    Dyring-Andersen, B; Geisler, C; Agerbeck, C
  • Interleukin 17A: Toward a new understanding of psoriasis pathogenesis
    Lynde, CW; Poulin, Y; Vender, R; Bourcier, M; Khalil, S
  • Blood to skin recirculation of CD4(+) memory T cells associates with cutaneous and systemic manifestations of psoriatic disease
    Diani, M; Galasso, M; Cozzi, C
  • Identification of a novel proinflammatory human skin-homing Vγ9Vδ2 T cell subset with a potential role in psoriasis
    Laggner, U; Di Meglio, P; Perera, GK
  • CCR6 marks regulatory T cells as a colon-tropic, IL-10-producing phenotype
    Kitamura, K; Farber, JM; Kelsall, BL
  • CCR6 is required for IL-23-induced psoriasis-like inflammation in mice
    Hedrick, MN; Lonsdorf, AS; Shirakawa, AK
  • CCR6 is required for epidermal trafficking of γδ-T cells in an IL-23-induced model of psoriasiform dermatitis
    Mabuchi, T; Singh, TP; Takekoshi, T
  • Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: Implications for psoriasis pathogenesis
    Harper, EG; Guo, C; Rizzo, H
  • Gain-of-function mutation of Card14 leads to spontaneous psoriasis-like skin inflammation through enhanced keratinocyte response to IL-17A
    Wang, M; Zhang, S; Zheng, G
  • PSORS2 is due to mutations in CARD14
    Jordan, CT; Cao, L; Roberson, ED
  • Increased frequency of activated CD8(+) T cell effectors in patients with psoriatic arthritis
    Diani, M; Casciano, F; Marongiu, L
  • Up-regulation of macrophage inflammatory protein-3 alpha/CCL20 and CC chemokine receptor 6 in psoriasis
    Homey, B; Dieu-Nosjean, MC; Wiesenborn, A
  • Early migration of cutaneous lymphocyte-associated antigen (CLA) positive T cells into evolving psoriatic plaques
    Davison, SC; Ballsdon, A; Allen, MH; Barker, JN
  • Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis
    Rao, DA; Gurish, MF; Marshall, JL
  • PD-1+CXCR5-CD4+T cells are correlated with the severity of systemic lupus erythematosus
    Lin, J; Yu, Y; Ma, J; Ren, C; Chen, W
  • Increased peripheral helper T cells type 17 subset correlates with the severity of psoriasis vulgaris
    Liu, W; Zhou, X; Wang, A; Ma, J; Bai, Y
  • Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model
    Hirota, K; Yoshitomi, H; Hashimoto, M
  • Differential requirement for CCR6 in IL-23-mediated skin and joint inflammation
    Shi, Z; Garcia-Melchor, E; Wu, X
  • Targeting the CCR6/CCL20 axis in entheseal and cutaneous inflammation
    Shi, Z; Garcia-Melchor, E; Wu, X
  • Polyfunctional, proinflammatory, tissue-resident memory phenotype and function of synovial interleukin-17A+CD8+ T cells in psoriatic arthritis
    Steel, KJA; Srenathan, U; Ridley, M
  • Brief report: Enrichment of activated group 3 innate lymphoid cells in psoriatic arthritis synovial fluid
    Leijten, EF; van Kempen, TS; Boes, M
  • Synovial cytokine expression in psoriatic arthritis and associations with lymphoid neogenesis and clinical features
    Celis, R; Planell, N; Fernandez-Sueiro, JL
  • Th17 gene expression in psoriatic arthritis synovial fluid and peripheral blood compared to osteoarthritis and cutaneous psoriasis
    Abji, F; Pollock, RA; Liang, K; Chandran, V; Gladman, DD
  • Essential role for CCR6 in certain inflammatory diseases demonstrated using specific antagonist and knockin mice
    Robert, R; Ang, C; Sun, G
  • IL-17-secreting γδ T cells are completely dependent upon CCR6 for homing to inflamed skin
    Campbell, JJ; Ebsworth, K; Ertl, LS
  • Efficacy of chemokine receptor inhibition in treating IL-36α-induced psoriasiform inflammation
    Campbell, JJ; Ebsworth, K; Ertl, LS
  • CCR6 and CCL20: Emerging players in the pathogenesis of rheumatoid arthritis
    Lee, AYS; Korner, H
  • Enthesitis: A hallmark of psoriatic arthritis
    Kaeley, GS; Eder, L; Aydin, SZ; Gutierrez, M; Bakewell, C
  • Anti-drug antibodies in psoriasis: A critical evaluation of clinical significance and impact on treatment response
    Hsu, L; Armstrong, AW
  • CCL20 neutralization by a monoclonal antibody in healthy subjects selectively inhibits recruitment of CCR6(+) cells in an experimental suction blister
    Bouma, G; Zamuner, S; Hicks, K
  • PHENIX: A comprehensive python-based system for macromolecular structure solution
    Adams, PD; Afonine, PV; Bunkoczi, G